Pou Serradell A, Lloreta Trull J, Corominas Torres J M, Hammouda E H, Urtizberea J A, Richard P, Brais B
Servicio de Neurología, Hospital Universitari del Mar, Barcelona.
Neurologia. 2004 Jun;19(5):239-47.
Autosomal dominant oculopharyngeal muscular dystrophy (OPMD), with late onset due to ptosis and/or dysphagia, is caused by short (GCG)8-13 triplet-repeat expansions in the polyadenylation binding protein 2 (PABP2) gene, which is localized in chromosome 14q11. The severity of the dominant OPMD as well as the number of expansions that cause the disease are variable. (GCG)9 is mentioned as the most frequent and the genotype/phenotype has still not been well-determined.
To describe the type of expansions (GCG)n found in Spanish families with OPMD, establishing if there is variability of them and the possible geno-phenotypical correlations.
Clinicopathological and molecular studies have been performed in 15 consecutive patients, belonging to seven Spanish families with OPMD. The muscular biopsy study under electronmicroscopy shows intranuclear inclusions (INIs) in all the examined patients (one patient per family). The genetic findings confirm the cause of the disease in all the affected members and in one clinically asymptomatic member of one recently examined family: three families (six, one and one studied members, respectively) present the (GCG)9 expansion, two families (one studied member each one) present the (GCG)10 expansion and two families (one and four studied members respectively) present the (GCG)11 expansion. In these 15 patients with a short GCG expansion causing OPMD, clinical tests for OPMD and a follow-up study of their clinical course have been carefully assessed: in patients with the (GCG)9 expansion major abnormalities appeared in extrinsic ocular mobility and more precocious presentation of limb girld (lumbopelvic preferentially) weakness leading to a great disability before the seventh decade of life under the seventies in some patients and sometimes leading to death. In patients with (GCG)10 and (GCG)11 expansions, eye movements are always preserved and the limb girld muscles weakness did not appear before the seventh decade. No correlation seems to exist between age of onset of the ptosis or dysphagia and the different (GCG)n expansions and the surgical treatment of ptosis, performed in eight patients, showed good results independently of the (GCG)n mutation.
Although further clinical and genetic studies are necessary to establish a strict genotype/phenotype correlation in OPMD, we concluded that the (GCG)9 expansion involve more severe phenotypes than those related to the (GCG)10 or (GCG)11 expansions. Therefore, genetic testing could benefit prognosis in asymptomatic individuals.
常染色体显性遗传性眼咽型肌营养不良症(OPMD),因上睑下垂和/或吞咽困难起病较晚,由位于14号染色体q11区的聚腺苷酸结合蛋白2(PABP2)基因中短的(GCG)8 - 13三联体重复序列扩增所致。显性OPMD的严重程度以及导致该疾病的扩增次数各不相同。(GCG)9被认为是最常见的,但其基因型/表型仍未完全明确。
描述西班牙OPMD家系中发现的(GCG)n扩增类型,确定其是否存在变异性以及可能的基因型与表型的相关性。
对来自7个西班牙OPMD家系的15例连续患者进行了临床病理和分子研究。所有受检患者(每个家系1例患者)的肌肉活检电镜检查均显示核内包涵体(INIs)。基因检测结果证实了所有受累成员以及最近检测的一个家系中一名临床无症状成员的病因:3个家系(分别有6例、1例和1例受检成员)存在(GCG)9扩增,2个家系(各有1例受检成员)存在(GCG)10扩增,2个家系(分别有1例和4例受检成员)存在(GCG)11扩增。在这15例因短GCG扩增导致OPMD的患者中,对OPMD的临床检测及其临床病程的随访研究进行了仔细评估:在(GCG)9扩增的患者中,主要异常出现在眼球外展活动,且肢体肌无力(优先为腰骨盆部)出现更早,导致部分患者在70岁前出现严重残疾,有时甚至导致死亡。在(GCG)10和(GCG)11扩增的患者中,眼球运动始终保留,肢体肌无力在70岁之前未出现。上睑下垂或吞咽困难的发病年龄与不同的(GCG)n扩增之间似乎没有相关性,8例患者进行的上睑下垂手术治疗显示,无论(GCG)n突变情况如何,效果均良好。
尽管需要进一步的临床和基因研究来确定OPMD中严格的基因型/表型相关性,但我们得出结论,(GCG)9扩增涉及的表型比(GCG)10或(GCG)11扩增相关的表型更严重。因此,基因检测可能有助于无症状个体的预后评估。